Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation

Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):315-8. doi: 10.1007/s00417-007-0669-3. Epub 2007 Oct 24.

Abstract

Background: To report a case of enlargement of the post photodynamic therapy treatment (PDT) spot in a patient with retinal angiomatous proliferation (RAP) that was treated with PDT combined with an intravitreal injection of bevacizumab.

Methods: 74-year-old woman with RAP due to age-related macular degeneration was treated with one verteporfin PDT session, sequenced by a single intravitreal injection of bevacizumab (1.25 mg) after 30 minutes.

Results: The patient's visual acuity (VA) at baseline was 20/200 and is now at the 10-month follow-up visit 20/400, while the RAP has disappeared according to the indocyanine angiography (ICG) findings. The post PDT hypofluorescent treatment spot has enlarged from 1,450 microm at the day of the treatment, to 5,360 microm at the 6-week visit. The patient is now at the 10-month follow-up visit and the hypofluorescence is still persisting.

Conclusion: The simultaneous combination of PDT with bevacizumab in patients with RAP may enhance the photochemical stress in normal choroid with prolonged and magnified hypofluorescence in ICG, due to ischemia in normal choriocapillaries.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Coloring Agents
  • Combined Modality Therapy
  • Female
  • Fluorescein Angiography
  • Fluorescence*
  • Humans
  • Indocyanine Green
  • Injections
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy
  • Photochemotherapy / adverse effects*
  • Photosensitizing Agents / adverse effects
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / adverse effects
  • Porphyrins / therapeutic use
  • Retina / drug effects*
  • Retinal Neovascularization / drug therapy*
  • Retinal Neovascularization / etiology*
  • Retinal Neovascularization / pathology
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Verteporfin
  • Visual Acuity
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Coloring Agents
  • Photosensitizing Agents
  • Porphyrins
  • Vascular Endothelial Growth Factor A
  • Verteporfin
  • Bevacizumab
  • Indocyanine Green